Skip to main content

MoneyWorks4Me

Lupin - Quaterly Results

05 Nov 2026 Evaluate
A decrease in the sales to Rs. 35673.40 millions was observed for the quarter ended September 2026. The sales stood at Rs. 40682.80 millions during the similar quarter previous year.The Net Loss for the quarter ended September 2026 is Rs. -59.10 millions as compared to Net Profit of Rs. 13573.50 millions of corresponding quarter ended September 2025Operating profit for the quarter ended September 2026 decreased to 3067.90 millions as compared to 12456.30 millions of corresponding quarter ended September 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 35673.40 40682.80 -12.31 107392.40 97768.70 9.84 195126.60 169675.00 15.00
Other Income 955.20 700.00 36.46 1980.00 1241.40 59.50 3127.70 1740.50 79.70
PBIDT 3067.90 12456.30 -75.37 41424.20 40294.10 2.80 81163.30 56465.30 43.74
Interest 325.50 277.80 17.17 681.10 466.80 45.91 1214.70 845.00 43.75
PBDT 1973.10 18105.30 -89.10 39973.80 45754.10 -12.63 84014.30 54848.10 53.18
Depreciation 1931.20 1747.20 10.53 3831.30 3514.50 9.01 7071.80 6476.90 9.18
PBT 41.90 16358.10 -99.74 36142.50 42239.60 -14.43 76942.50 48371.20 59.07
TAX 101.00 2784.60 -96.37 9055.60 7385.40 22.61 13276.90 8641.60 53.64
Deferred Tax 68.70 -87.70 -178.34 97.60 -2.30 -4343.48 -236.00 70.40 -435.23
PAT -59.10 13573.50 -100.44 27086.90 34854.20 -22.29 63665.60 39729.60 60.25
Equity 914.60 913.60 0.11 914.60 913.60 0.11 914.40 913.20 0.13
PBIDTM(%) 8.60 30.62 -71.91 38.57 41.21 -6.41 41.60 33.28 24.99
Peers
Company Name CMP
Sun Pharma. Inds. 1915.10
Dr. Reddys Labs. 1369.00
Cipla 1410.95
Lupin 1995.00
Zydus Lifesciences 1200.00
View more..